Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

Safety of daptomycin in patients with renal impairment

01-dic-2010 | Revista: Medicina Clínica

Azanza JR, Quetglas EG.
Servicio de Farmacología Clínica, Clínica Universidad de Navarra, Facultad de Medicina, Universidad de Navarra, Pamplona, España


RESUMEN

Daptomycin is a lipopeptide bactericidal antimicrobial indicated in the treatment of skin and soft tissue infections (SSTI), Staphylococcus aureus-related right-sided infective endocarditis (RIE) and bacteremia secondary to these infections.

The recommended dosage in patients with previous renal impairment is 4 mg/kg/48 hours in SSTI. There are no data published for SSTI and RIE followed by bacteremia. Based on pharmacokinetic models, the recommended dosage in patients under hemodialysis is 4 mg/kg after dialysis.

The present article aims to review of the latest published data on daptomycin use in patients with renal impairment and to relate these findings to preliminary data from the EUCORE registry in Spain.

CITA DEL ARTÍCULO  Med Clin (Barc). 2010 Dec;135 Suppl 3:55-9